FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955497129> ?p ?o ?g. }

• W2955497129 endingPage "1153" @default.
• W2955497129 startingPage "1153" @default.
• W2955497129 abstract "Palmoplantar pustulosis (PPP) causes erythematous, scaly plaques with recurrent sterile pustules refractory to treatment and with few randomized clinical trials conducted. Evidence points to involvement of interleukin 23 in the pathogenesis of PPP.To determine the efficacy and safety of guselkumab, an anti-IL-23 monoclonal antibody, in Japanese patients with PPP.A phase 3 randomized clinical trial was conducted from December 15, 2015, to December 12, 2017. A total of 159 enrolled patients (aged ≥20 years) had an inadequate response to conventional therapies, with a diagnosis of PPP for 24 or more weeks before screening. Intention-to-treat analysis was performed.Subcutaneous injections of guselkumab, 100 or 200 mg, at weeks 0, 4, and 12, and every 8 weeks thereafter were administered; placebo was given at weeks 0, 4, and 12.Changes from baseline in PPP Area and Severity Index (PPPASI) score (possible score range, 0-72, with higher scores indicating greater area and severity), PPP severity index (PPSI) score (possible score range, 0-12, with higher scores indicating greater severity), and proportion of PPPASI-50 (≥50% reduction) responders at weeks 16 and 52 were assessed. Safety was monitored through week 52.A total of 159 patients (mean [SD] age at diagnosis, 46.8 [11.9] years; 126 women [79.2%]) were enrolled. Treatment groups comprised guselkumab, 100 mg (n = 54), guselkumab, 200 mg (n = 52), or placebo (n = 53). Both guselkumab groups demonstrated significant improvement in least-squares mean changes in PPPASI score compared with placebo: -15.3 and -11.7 in the guselkumab 100-mg and 200-mg groups, respectively, and -7.6 in the placebo group (difference [SE] vs placebo: -7.7 [1.7] in the 100-mg group, P < .001; 95% CI, -11.00 to -4.38; and -4.1 [1.7] in the 200-mg group, P < .017; 95% CI, -7.47 to -0.75]). Least-squares mean changes in PPSI score showed significant improvement in both guselkumab groups (100 mg: -2.0 [0.5]; P < .001; 95% CI, -2.96 to -0.95; 200 mg: -1.0 [0.5; P = .04; 95% CI, -2.06 to -0.03). A significantly higher proportion of patients in the guselkumab 100-mg group (31 [57.4%]) achieved a PPPASI-50 response at week 16 vs placebo (18 [34.0%]; P = .02); however, the result was not significant for the guselkumab 200-mg group (19 [36.5%]) vs placebo; P = .78). Each efficacy end point improved consistently through week 52. Health-related quality of life improved significantly as indicated by a reduction in the Dermatology Life Quality Index score (100 mg: -2.6; 95% CI, -4.0 to -1.2; P < .001; 200 mg: -1.6; 95% CI, -3.1 to -0.2; P = .03). Serious treatment-emergent adverse events were observed in 8 patients (placebo group, 2 of 53 [3.8%]; combined guselkumab group, 6/157≠10.5%). No serious infections were reported.Targeting interleukin 23 with guselkumab may be an effective and safe treatment option for a recalcitrant disease such as PPP.ClinicalTrials.gov identifier: NCT02641730." @default.
• W2955497129 created "2019-07-12" @default.
• W2955497129 creator A5010097586 @default.
• W2955497129 creator A5011912105 @default.
• W2955497129 creator A5013454968 @default.
• W2955497129 creator A5028608906 @default.
• W2955497129 creator A5046048391 @default.
• W2955497129 creator A5081072346 @default.
• W2955497129 creator A5082985665 @default.
• W2955497129 creator A5089950279 @default.
• W2955497129 date "2019-10-01" @default.
• W2955497129 modified "2023-10-09" @default.
• W2955497129 title "Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis" @default.
• W2955497129 cites W1759569004 @default.
• W2955497129 cites W1970559779 @default.
• W2955497129 cites W1991314184 @default.
• W2955497129 cites W1998987703 @default.
• W2955497129 cites W2004186675 @default.
• W2955497129 cites W2021238107 @default.
• W2955497129 cites W2061205096 @default.
• W2955497129 cites W2064709295 @default.
• W2955497129 cites W2071343804 @default.
• W2955497129 cites W2159058814 @default.
• W2955497129 cites W2165609128 @default.
• W2955497129 cites W2344070907 @default.
• W2955497129 cites W2570140560 @default.
• W2955497129 cites W2570141807 @default.
• W2955497129 cites W2592119101 @default.
• W2955497129 cites W2738316552 @default.
• W2955497129 cites W2769138774 @default.
• W2955497129 cites W2775424386 @default.
• W2955497129 cites W2789890489 @default.
• W2955497129 cites W2883167586 @default.
• W2955497129 cites W4229771498 @default.
• W2955497129 cites W4236548038 @default.
• W2955497129 cites W4241408694 @default.
• W2955497129 cites W4242901398 @default.
• W2955497129 cites W4253997148 @default.
• W2955497129 cites W4292528167 @default.
• W2955497129 doi "https://doi.org/10.1001/jamadermatol.2019.1394" @default.
• W2955497129 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6613288" @default.
• W2955497129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31268476" @default.
• W2955497129 hasPublicationYear "2019" @default.
• W2955497129 type Work @default.
• W2955497129 sameAs 2955497129 @default.
• W2955497129 citedByCount "58" @default.
• W2955497129 countsByYear W29554971292019 @default.
• W2955497129 countsByYear W29554971292020 @default.
• W2955497129 countsByYear W29554971292021 @default.
• W2955497129 countsByYear W29554971292022 @default.
• W2955497129 countsByYear W29554971292023 @default.
• W2955497129 crossrefType "journal-article" @default.
• W2955497129 hasAuthorship W2955497129A5010097586 @default.
• W2955497129 hasAuthorship W2955497129A5011912105 @default.
• W2955497129 hasAuthorship W2955497129A5013454968 @default.
• W2955497129 hasAuthorship W2955497129A5028608906 @default.
• W2955497129 hasAuthorship W2955497129A5046048391 @default.
• W2955497129 hasAuthorship W2955497129A5081072346 @default.
• W2955497129 hasAuthorship W2955497129A5082985665 @default.
• W2955497129 hasAuthorship W2955497129A5089950279 @default.
• W2955497129 hasBestOaLocation W29554971291 @default.
• W2955497129 hasConcept C121332964 @default.
• W2955497129 hasConcept C126322002 @default.
• W2955497129 hasConcept C141071460 @default.
• W2955497129 hasConcept C142424586 @default.
• W2955497129 hasConcept C142724271 @default.
• W2955497129 hasConcept C16005928 @default.
• W2955497129 hasConcept C168563851 @default.
• W2955497129 hasConcept C204787440 @default.
• W2955497129 hasConcept C27081682 @default.
• W2955497129 hasConcept C2776173921 @default.
• W2955497129 hasConcept C2779134260 @default.
• W2955497129 hasConcept C2780564577 @default.
• W2955497129 hasConcept C2909516574 @default.
• W2955497129 hasConcept C71924100 @default.
• W2955497129 hasConcept C87355193 @default.
• W2955497129 hasConcept C90924648 @default.
• W2955497129 hasConceptScore W2955497129C121332964 @default.
• W2955497129 hasConceptScore W2955497129C126322002 @default.
• W2955497129 hasConceptScore W2955497129C141071460 @default.
• W2955497129 hasConceptScore W2955497129C142424586 @default.
• W2955497129 hasConceptScore W2955497129C142724271 @default.
• W2955497129 hasConceptScore W2955497129C16005928 @default.
• W2955497129 hasConceptScore W2955497129C168563851 @default.
• W2955497129 hasConceptScore W2955497129C204787440 @default.
• W2955497129 hasConceptScore W2955497129C27081682 @default.
• W2955497129 hasConceptScore W2955497129C2776173921 @default.
• W2955497129 hasConceptScore W2955497129C2779134260 @default.
• W2955497129 hasConceptScore W2955497129C2780564577 @default.
• W2955497129 hasConceptScore W2955497129C2909516574 @default.
• W2955497129 hasConceptScore W2955497129C71924100 @default.
• W2955497129 hasConceptScore W2955497129C87355193 @default.
• W2955497129 hasConceptScore W2955497129C90924648 @default.
• W2955497129 hasIssue "10" @default.
• W2955497129 hasLocation W29554971291 @default.
• W2955497129 hasLocation W29554971292 @default.
• W2955497129 hasLocation W29554971293 @default.
• W2955497129 hasLocation W29554971294 @default.

• next